is indicated in chronic inflammatory bowel diseases (ulcerative colitis, Crohn’s disease), to induce and maintain remission.
The active substance mesalazine acts topically and not systematically.
Antiinflammatory action results from inhibition of cyclooxygenase and therefore reducing the production of prostaglandins in colon, which feed inflammation.
| DRUG ACTIVE SUBSTANCE | CONTENT | PHARMACEUTICAL FORM | PACKAGING | THERAPEUTICAL CATEGORY |
| Mesalazin | 500 mg/G.R. tab | Gastroresistant tablets | BT x 50 δισκία | Treating idiopathic inflammatory bowel disease |